After announcing positive results showing that its Stentrode BCI is safe in six patients, brain-computer interface company Synchron is planning a pivotal trial to eventually file for FDA approval.

Despite the availability of more than 20 anti-epilepsy drugs, surgery, and a neurostimulation therapy that’s been available for 15 years, a large proportion of the three million patients in the US with epilepsy continue to have seizures. Emerging device companies aim to provide a solution for them.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.